Astria Therapeutics to Present at Upcoming European Academy of Allergy and Clinical Immunology Congress

Astria Therapeutics to Present at Upcoming European Academy of Allergy and Clinical Immunology Congress

Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced that it will present two posters at the upcoming European Academy of Allergy and Clinical Immunology (EAACI) Congress in Valencia, Spain on June 1, 2024.

  • Dr. Marcus Maurer, M.D., Professor of Dermatology and Allergy at Charité Universitätsmedizin in Berlin, will present information on ALPHA-SOLAR, a long-term open-label trial of STAR-0215 in people living with HAE, in a poster titled "Rationale and Design of the ALPHA-SOLAR Clinical Trial of STAR-0215 for the Treatment of Hereditary Angioedema (HAE)." The poster session will take place on Saturday, June 1 at 12:00pm CEST.
  • Nikos Biris, Ph.D., Senior Director of Assay Development at Astria Therapeutics, will present information on the characterization of STAR-0310 in a poster titled "Development and Characterization of STAR-0310: a Novel OX40 Antagonistic Monoclonal Antibody." The poster session will take place on Saturday, June 1 at 12:00pm CEST.

About Astria Therapeutics:

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development for the treatment of hereditary angioedema. Our second program, STAR-0310, is a monoclonal antibody OX40 antagonist in preclinical development for the treatment of atopic dermatitis. Learn more about our company on our website, www.astriatx.com , or follow us on X and Instagram @AstriaTx and on Facebook and LinkedIn.

Astria Contact:
Investor Relations and Media:
Elizabeth Higgins
investors@astriatx.com

News Provided by Business Wire via QuoteMedia

ATXS:US
The Conversation (0)
Astria Therapeutics to Present at Upcoming Jefferies Healthcare Conference

Astria Therapeutics to Present at Upcoming Jefferies Healthcare Conference

Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will participate in a fireside chat at the upcoming Jefferies Healthcare... Keep Reading...
Astria Therapeutics to Present at Upcoming Eastern Allergy Conference

Astria Therapeutics to Present at Upcoming Eastern Allergy Conference

Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced that it will present final STAR-0215 Phase 1a healthy subject data in an encore presentation at the upcoming Eastern Allergy... Keep Reading...
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635

Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635

Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, granted stock options to purchase 173,500 shares of Astria's common stock on May 1, 2024 under Astria's 2022 Inducement Stock Incentive... Keep Reading...
VVC - Purchase of Ithaca 1-17 Well and 5 Mile Pipeline

VVC - Purchase of Ithaca 1-17 Well and 5 Mile Pipeline

VVC Exploration Corporation, dba VVC Resources ("VVC" or the "Company") (TSX-V: VVC; OTC: VVCVF) announces that Plateau Helium Corporation ("PHC"), a wholly owned subsidiary of the Company, has completed the purchase of the Ithaca 1-17 well together with approximately five miles of associated... Keep Reading...
Canadian Investment Regulatory Organization Trade Resumption - ANT

Canadian Investment Regulatory Organization Trade Resumption - ANT

Trading resumes in: Company: Anteros Metals Inc. CSE Symbol: ANT All Issues: Oui Resumption (ET): 11:15 AM CIRO can make a decision to impose a temporary suspension (halt) of trading in a security of a publicly-listed company. Trading halts are implemented to ensure a fair and orderly market.... Keep Reading...
Anteros Metals Enters Definitive Agreement

Anteros Metals Enters Definitive Agreement

Anteros Metals Inc. (CSE: ANT) ("Anteros" or the "Company") is pleased to announce that, further to its press release of October 7, 2025, the Company and Rift Minerals Inc. ("Rift") have entered into an option and joint venture agreement (the "Agreement") dated October 8, 2025, pursuant to which... Keep Reading...
Strategic Option Secured Over Feather Cap Gold Project

Strategic Option Secured Over Feather Cap Gold Project

Corazon Mining (CZN:AU) has announced Strategic Option Secured Over Feather Cap Gold ProjectDownload the PDF here. Keep Reading...
1,173 Soil Geochemistry Samples Completed

1,173 Soil Geochemistry Samples Completed

Augustus Minerals (AUG:AU) has announced 1,173 Soil Geochemistry Samples CompletedDownload the PDF here. Keep Reading...
Canada One Acquires 4,836 ha Copper-Gold Property Adjacent to Copper Mountain Mine

Canada One Acquires 4,836 ha Copper-Gold Property Adjacent to Copper Mountain Mine

Canada One Mining Corp. (TSXV: CONE) (OTC Pink: COMCF) (FSE: AU31) ("Canada One" or the "Company") announces it has agreed to acquire a 4,836-hectare copper-gold property contiguous to the northwest of Hudbay Minerals' Copper Mountain Mine, to be known as "Copper Dome North" (the... Keep Reading...

Latest Press Releases

Related News